JP2019519528A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519528A5
JP2019519528A5 JP2018561641A JP2018561641A JP2019519528A5 JP 2019519528 A5 JP2019519528 A5 JP 2019519528A5 JP 2018561641 A JP2018561641 A JP 2018561641A JP 2018561641 A JP2018561641 A JP 2018561641A JP 2019519528 A5 JP2019519528 A5 JP 2019519528A5
Authority
JP
Japan
Prior art keywords
polypeptide
domain monomer
domain
sequence
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519528A (ja
JP7045333B6 (ja
JP7045333B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034084 external-priority patent/WO2017205434A1/en
Publication of JP2019519528A publication Critical patent/JP2019519528A/ja
Publication of JP2019519528A5 publication Critical patent/JP2019519528A5/ja
Priority to JP2022044109A priority Critical patent/JP7295301B2/ja
Application granted granted Critical
Publication of JP7045333B2 publication Critical patent/JP7045333B2/ja
Publication of JP7045333B6 publication Critical patent/JP7045333B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561641A 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法 Active JP7045333B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022044109A JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたFcコンストラクトに関する組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US62/340,322 2016-05-23
US201762443451P 2017-01-06 2017-01-06
US62/443,451 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022044109A Division JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたFcコンストラクトに関する組成物及び方法

Publications (4)

Publication Number Publication Date
JP2019519528A JP2019519528A (ja) 2019-07-11
JP2019519528A5 true JP2019519528A5 (https=) 2020-07-02
JP7045333B2 JP7045333B2 (ja) 2022-03-31
JP7045333B6 JP7045333B6 (ja) 2022-05-06

Family

ID=60412547

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018561641A Active JP7045333B6 (ja) 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法
JP2018561639A Withdrawn JP2019519527A (ja) 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法
JP2022010912A Pending JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたFcコンストラクトに関する組成物及び方法
JP2022044109A Active JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたFcコンストラクトに関する組成物及び方法
JP2024193057A Withdrawn JP2025026880A (ja) 2016-05-23 2024-11-01 操作されたFcコンストラクトに関する組成物及び方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018561639A Withdrawn JP2019519527A (ja) 2016-05-23 2017-05-23 操作されたFcコンストラクトに関する組成物及び方法
JP2022010912A Pending JP2022068176A (ja) 2016-05-23 2022-01-27 操作されたFcコンストラクトに関する組成物及び方法
JP2022044109A Active JP7295301B2 (ja) 2016-05-23 2022-03-18 操作されたFcコンストラクトに関する組成物及び方法
JP2024193057A Withdrawn JP2025026880A (ja) 2016-05-23 2024-11-01 操作されたFcコンストラクトに関する組成物及び方法

Country Status (14)

Country Link
US (4) US11155640B2 (https=)
EP (2) EP3484514B1 (https=)
JP (5) JP7045333B6 (https=)
KR (3) KR102590061B1 (https=)
CN (4) CN118206639A (https=)
AU (2) AU2017272109B2 (https=)
BR (2) BR112018074056A2 (https=)
CA (2) CA3025310A1 (https=)
DK (1) DK3484514T3 (https=)
ES (1) ES2973251T3 (https=)
IL (3) IL263211B2 (https=)
PL (1) PL3484514T3 (https=)
SG (3) SG11201810465RA (https=)
WO (2) WO2017205436A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP7146771B2 (ja) * 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたFcコンストラクトに関する組成物及び方法
US20210284717A1 (en) * 2018-07-11 2021-09-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
CN113382749A (zh) * 2018-07-11 2021-09-10 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
CA3106212A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
KR20210044783A (ko) * 2018-07-11 2021-04-23 모멘타 파머슈티컬스 인코포레이티드 CTLA-4 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
US20210238310A1 (en) * 2018-07-11 2021-08-05 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
MX2021000307A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
JP2021530989A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド PD−L1を標的とした改変されたFc抗原結合ドメイン構築体に関する組成物および方法
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
BR112022010096A2 (pt) * 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
EP4255933A4 (en) * 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2257861A1 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
EP2432451A2 (en) 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス,インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白fc組合物之天然人類蛋白質片段之融合蛋白
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Fc領域を含むモノマーポリペプチド及び使用方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
ES2623912T3 (es) * 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
IN2013MN01438A (https=) 2011-03-17 2015-06-12 Univ Ramot
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
WO2013185113A1 (en) * 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
HK1209034A1 (en) 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
BR112015008663B1 (pt) * 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104558194B (zh) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
EP3082847A1 (en) * 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
CN113248613B (zh) 2014-01-15 2024-08-23 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP7146771B2 (ja) * 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたFcコンストラクトに関する組成物及び方法

Similar Documents

Publication Publication Date Title
JP2019519528A5 (https=)
TWI648401B (zh) 生長分化因子15(gdf-15)構築體
ES2752248T3 (es) Heterodímero proteínico y uso del mismo
JP2017529326A5 (https=)
JP2020011959A5 (https=)
JP2014521684A5 (https=)
JP2011502954A5 (https=)
JP2019519215A5 (https=)
JP2016516016A5 (https=)
JP2017538395A5 (https=)
JP2017523184A5 (https=)
JP2010516290A5 (https=)
JP2013542913A5 (https=)
JP2016529229A5 (https=)
JP7834637B2 (ja) 治療用融合タンパク質
JP2010518079A5 (https=)
JP2017536337A5 (https=)
RU2017114673A (ru) Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение
JP2017500316A5 (https=)
JP2016536369A5 (https=)
JP2015524413A5 (https=)
JP2020509737A5 (https=)
JP2019500026A5 (https=)
JP2021514003A5 (https=)
Hong et al. substance-P prevents cardiac ischemia-reperfusion injury by modulating stem cell mobilization and causing early suppression of injury-mediated inflammation.